Abbott Reports 10.5% EPS Growth for Fiscal Q2
Q2 revenue beat expectations at $11.14 billion, up 7.4% year over year.
Adjusted EPS exceeded estimates, reaching $1.26 for Q2 2025, representing 10.5% growth year over year.
Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure.
These 10 stocks could mint the next wave of millionaires ›
Abbott Laboratories (NYSE:ABT), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that narrowly topped analysts' consensus estimates. Q2 revenue climbed to $11.14 billion, surpassing the analyst estimate of $11.06 billion, and adjusted earnings per share came in at $1.26, beating the consensus by $0.01.
These results reflect robust year-over-year growth, especially in the company's Medical Devices segment, which reported year-over-year sales growth of 13.4%, but also highlight continued headwinds in its Diagnostics business, mainly in China. Overall, the company achieved margin expansion and affirmed management's full-year outlook despite tariff pressures and competitive and regulatory challenges overseas.
Metric Q2 2025 Q2 2025 Estimate Q2 2024 Change (YOY)
Adjusted EPS $1.26 $1.25 $1.14 10.5%
Revenue $11.14 billion $11.06 billion $10.38 billion 7.4%
Adj. operating margin 22.9% 21.9% 100 bps
Net earnings $2.21 billion $2.00 billion 10.5%
Source: Abbott Laboratories. Note: Analysts' consensus estimates for the quarter provided by FactSet. YOY = Year over year. bps = basis points.
Understanding Abbott Laboratories' Business
Abbott Labs operates across four main segments: medical devices, diagnostics, nutrition, and pharmaceuticals. Its product range includes continuous glucose monitors for diabetes care, implantable heart devices, laboratory diagnostic analyzers, and nutritional products such as Ensure and Glucerna. The company serves customers in over 160 countries, generating a significant portion of sales internationally.
The company's ongoing strategy centers on technological innovation, shown in products like its FreeStyle Libre system for continuous glucose monitoring, and compliance with evolving global health regulations. Its global footprint supports market access and supply chain resilience. Success depends on delivering new technology, defending market share, and adapting to changing healthcare policies and competitive pressures.
Second-Quarter Highlights
The Medical Devices segment was the standout performer. Sales for the segment reached $5.37 billion, up 13.4%, with especially strong contributions from Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology subsegments. Continuous glucose monitoring systems, like the FreeStyle Libre, generated $1.9 billion in revenue -- up 21.4% on a reported basis -- helped by robust adoption in both the U.S. and international markets. New launches, such as Navitor for heart valves and AVEIR leadless pacemakers, also fueled growth.
Diagnostics segment sales came in at $2.17 billion, declining 1% from last year. The primary factor was a sharp drop in COVID-19 testing sales, now down to $55 million from $102 million a year earlier. Core Laboratory Diagnostics grew slightly, but ongoing price cuts from China's volume-based procurement program pressured overall segment results. While diagnostics achieved roughly 7% growth outside China in Q1 2025, this did not fully make up for the shortfall in that market. CEO Robert Ford noted the challenge, highlighting that recent changes in Chinese procurement have led to lower prices without offsetting volume gains -- a departure from past patterns.
Nutrition revenue was $2.21 billion, up 2.9% on a reported basis. Adult Nutrition -- driven by Ensure and Glucerna brands -- grew 6.1% on a reported basis, while Pediatric Nutrition organic sales remained nearly flat, reflecting a continuing squeeze in international pediatric sales, which fell 5.7%. The adult product growth offset ongoing softness in pediatric lines. Pharmaceutical sales, mostly in established branded generics outside the United States, rose 6.9% on a reported basis, with double-digit gains in emerging markets across Asia, Latin America, and the Middle East.
Adjusted operating margin rose to 22.9%, a 100 basis point increase from the prior year. Management cautioned that tariffs introduced in 2025 posed a 'few hundred million dollar' headwind for the second half of the year, but indicated that mitigation strategies -- such as adjusting manufacturing footprints and leveraging foreign exchange rates -- remain in progress. Net earnings reached $2.21 billion. Abbott Laboratories also maintained a quarterly dividend of $0.59 per share, extending its streak of increases to 53 consecutive years.
Future Outlook and What to Watch
Looking ahead, management reaffirmed its full-year guidance despite new tariff costs. For fiscal 2025, it projects organic sales growth (excluding COVID-19 testing-related sales) of 7.5% to 8.0%, and full-year adjusted EPS in the $5.10–$5.20 range. Third-quarter 2025 adjusted EPS is expected to be between $1.28 and $1.32. Abbott also guided to an adjusted operating margin of 23.5%, implying further focus on efficiency and cost controls. Management sees new product launches and recovery in underperforming segments as growth drivers for the back half of 2025.
Investors should closely monitor the ongoing impact of global tariffs, continued performance in the Diagnostics segment -- especially in China -- and the pace at which the company launches new products in its medical devices pipeline. International pediatric nutrition trends also bear watching, given ongoing weakness. Planned mitigation efforts around tariffs and supply chain reshuffling, along with the evolving clinical and regulatory landscape, are likely to influence the company's performance as 2025 progresses.
Note: Revenue and net income are presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,059%* — a market-crushing outperformance compared to 180% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of July 14, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Alphabet and Apple
For Immediate Release Chicago, IL – July 18, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet GOOGL and Apple AAPL. Here are highlights from Thursday's Analyst Blog: Alphabet vs. Apple: Which Consumer AI Stock Is the Better Buy Right Now? Alphabet and Apple are the two most well-known providers of consumer apps marketplaces through Google Pay Store and Apple App Store, respectively. The companies are taking initiatives to infuse artificial intelligence (AI) into their consumer-centric offerings to expand their user base and boost market share. Unlike enterprises and businesses, individual consumers have been much cautious to adopt AI and generative AI (Gen AI) into their daily lifestyle and routines. Per a Bain & Company December 2024 survey, only 35% of U.S. consumers used Gen AI in comparison to 95% of U.S. and European companies. Concerns around privacy, accuracy and data security have hindered proliferation among individual consumers. However, the scenario seems to have changed in the past six months of 2025. As per a latest report by Menlo Ventures, almost 61% of U.S. adults (survey sample of more than 5,000 U.S. adults) have used AI over the past six months, and nearly 19% have made it a habit to use it on a daily basis. Although monetization remains weak (only 3% paying for premium services among an estimated user base of 1.8 billion), the growing infusion of AI tools into consumer lifestyle that makes users complete their daily routine in a better, faster and cheaper way is expected to boost spending. According to the New Minds, New Markets study by Cognizant in collaboration with Oxford Economics, the 18–44-year-old AI enthusiasts will "command an estimated $4.4 trillion of AI-influenced consumer spending in the U.S. by 2030," driven by a rise in income and purchasing power. For the United Kingdom, Australia and Germany, the projection stands at $690 billion, $669 billion, and $539 billion, respectively. Alphabet and Apple are well-poised to cultivate this huge opportunity. Nevertheless, GOOGL or AAPL, which has an edge under the current scenario? The Case for GOOGL Stock Alphabet's open and cloud-centric approach has been driving the popularity of its applications among consumers. In first-quarter 2025, Alphabet surpassed 270 million paid subscriptions with YouTube and Google One as key drivers. Google Assistant, now called Gemini, is the #2-ranked general AI assistant in terms of usage (23% share) among all U.S. adults as per Menlo Ventures' survey, beating Apple Siri, which is in the #5 position (16% share). Alphabet's initiatives to deploy AI and infuse AI in Search are driving top-line growth. Search revenues are driven by improving engagement with features like AI Overview, which now has 1.5 billion users per month and is available in more than 15 languages across 140 countries. The addition of AI mode expands AI Overview's advanced reasoning, thinking and multimodal capabilities. Advancements in the latest Gemini models are helping Alphabet to upgrade AI Overviews with easier-to-read responses, breaking down key information and incorporating more visuals directly into responses. Circle to Search is driving additional Search and is gaining popularity among younger users. Circle to Search, which is currently available on more than 300 million Android devices, is expected to gain further popularity with the addition of AI Mode. Circle to Search can now be used to get instant help during gaming on mobile. The Case for AAPL Stock Apple is seeing better iPhone 16 sales in regions where Apple Intelligence is available. Apple expanded the availability of Apple Intelligence with iOS 18.4, iPadOS 18.4, and macOS Sequoia 15.4 updates in new languages, including French, German, Italian, Portuguese (Brazil), Spanish, Japanese, Korean, and Chinese (simplified) — as well as localized English for Singapore and India — and are accessible in nearly all regions around the world. At the end of 2025, Apple Intelligence will be available in eight more languages: Danish, Dutch, Norwegian, Portuguese, Swedish, Turkish, Chinese (traditional) and Vietnamese. New Apple Intelligence features, such as Live Translation, updates to visual intelligence, as well as enhancements to Image Playground and Genmoji, are noteworthy. Shortcuts can access Apple Intelligence directly. Apple Intelligence is now getting added to Apple Wallet, and users can make purchases with Apple Pay. However, Apple Intelligence continues to lag the "WoW" factor, which has been a concern. Delayed and staggered launches are other concerns. GOOGL Earnings Estimate Revision Positive, AAPL's Goes South The Zacks Consensus Estimate for GOOGL's 2025 earnings is pegged at $9.56 per share, up 3 cents over the past 60 days, indicating an 18.91% increase over 2024's reported figure. The consensus mark for Apple's fiscal 2025 earnings has declined by a penny to $7.10 per share over the past 60 days, suggesting 5.19% growth over fiscal 2024. Alphabet Shares Outperform Apple Shares of Alphabet and Apple have suffered from challenging macroeconomic conditions, volatility related to higher tariffs and increasing regulatory concerns. Year to date, GOOGL shares have lost 3.3%, outperforming Apple's decline of 16%. Valuation: Alphabet's P/S Ratio is Cheaper Than Apple In terms of forward 12-month Price/Sales (P/S), Apple shares are trading at 7.52X, higher than Alphabet's 6.41X. While Apple has a Value Score of D, Alphabet carries a Value Score of C, suggesting both shares are overvalued. Here's Why Alphabet Is a Better Consumer AI Stock Right Now Alphabet is benefiting from the growing popularity of Gemini, AI Overview and Circle to Search among consumers. Continuous innovation across search, productivity and developer tools is a key catalyst for Alphabet. In comparison, Apple is still playing a catch-up role with Apple Intelligence. Currently, Alphabet has a Zacks Rank #2 (Buy), making the stock a stronger pick compared with Apple, which has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
Globe and Mail
28 minutes ago
- Globe and Mail
Digi International to Release Third Fiscal Quarter 2025 Earnings Results and Host a Conference Call on August 6, 2025
Digi International® Inc. (NASDAQ: DGII) will release its financial results for the third fiscal quarter 2025 on Wednesday, August 6, after market close, at approximately 4:00 p.m. ET. Ron Konezny, CEO, and Jamie Loch, CFO, will host a conference call later the same day, at 5:00 p.m. ET, to briefly discuss the results and will take questions and provide answers. Please click here to pre-register for the conference call and obtain your dial in number and passcode. All participants are asked to dial-in 15 minutes prior to the start time. Participants may access a live webcast of the conference call through the investor relations section of Digi's website, or the hosting website here. A replay will be available within approximately two hours after the completion of the call. You may access the replay via webcast through the investor relations section of Digi's website. The webcast will be available for replay for approximately one year. About Digi International Delivering Scalable Solutions for What's Next Since 1985, Digi International Inc. (Digi) has been a pioneer in wireless communication, forging the future for connected devices and responding to the needs of the people and enterprises that use them. Before the Internet of Things was a thing, we built M2M and IoT devices, adapted to evolving network standards, and optimized data communications around the most advanced protocols and emerging technologies. From radio frequency modems to gateways, cellular routers, networking devices, embedded system-on-modules (SOM) and single-board computers (SBCs), Digi's solutions have continually grown to serve an extensive breadth of applications across the IoT landscape. Today, our IoT offering includes sensor-based solutions, a sophisticated platform for remotely monitoring device deployments of any size, anywhere, as well as professional design, implementation and certification teams to help you carry out your vision, no matter how large or small.
Globe and Mail
28 minutes ago
- Globe and Mail
Securities Lawsuit Alert: Organon & Co. (OGN) - Contact Levi & Korsinsky Before July 22, 2025
New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Organon & Co. (NYSE: OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Organon & Co. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Organon stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
